Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.48 HKD | +0.65% | +12.24% | -21.36% |
Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
Business Summary
Number of employees: 1,494
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vaccine Products
100.0
%
| 1,203 | 100.0 % | 395 | 100.0 % | -67.20% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
99.1
%
| 945 | 78.8 % | 378 | 99.1 % | -60.01% |
Foreign
0.9
%
| 254 | 21.2 % | 3 | 0.9 % | -98.63% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hui Hua Mao
FOU | Founder | 62 | 09-01-12 |
Tao Zhu
FOU | Founder | 51 | 09-01-12 |
Xue Feng Yu
CEO | Chief Executive Officer | 60 | 09-01-12 |
Dong Xu Qiu
FOU | Founder | 64 | 09-01-12 |
Ming Liu
DFI | Director of Finance/CFO | 43 | 21-05-31 |
Jun Qiang Li
CTO | Chief Tech/Sci/R&D Officer | - | - |
Shou Bai Chao
COO | Chief Operating Officer | 61 | 18-04-30 |
Jing Wang
BRD | Director/Board Member | 42 | 12-05-31 |
Zhong Qi Shao
BRD | Director/Board Member | 61 | 10-12-31 |
Jin Cui
SEC | Corporate Secretary | 37 | 16-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wing Yu Leung
BRD | Director/Board Member | 53 | 15-08-31 |
Shou Bai Chao
COO | Chief Operating Officer | 61 | 18-04-30 |
Dong Xu Qiu
FOU | Founder | 64 | 09-01-12 |
Shui Fa Gui
BRD | Director/Board Member | 58 | 19-11-28 |
Xue Feng Yu
CEO | Chief Executive Officer | 60 | 09-01-12 |
Tao Zhu
FOU | Founder | 51 | 09-01-12 |
Zhong Qi Shao
BRD | Director/Board Member | 61 | 10-12-31 |
Zhi Xiao
CHM | Chairman | 45 | 19-06-27 |
Jing Wang
BRD | Director/Board Member | 42 | 12-05-31 |
Jian Zhong Liu
BRD | Director/Board Member | 59 | 19-11-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 114,778,999 | 0 | 0 | 39.30 % |
Stock B | 1 | 132,670,900 | 97,253,029 ( 73.30 %) | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CANSINO BIOLOGICS INC. 1.00% | 670,148 | 1.00% | 4,594,407 $ |
Company contact information
CanSino Biologics, Inc.
4/F, Room 401-420, Biomedical Park 185 South Avenue
300457, Tianjin
+86 022 5821 3600
http://www.cansinotech.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.04% | 1.06B | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-21.76% | 29.36B | |
+58.56% | 24.49B | |
-14.78% | 17.31B | |
-18.49% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- 6185 Stock
- Company CanSino Biologics Inc.